MX2019000091A - Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. - Google Patents
Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.Info
- Publication number
- MX2019000091A MX2019000091A MX2019000091A MX2019000091A MX2019000091A MX 2019000091 A MX2019000091 A MX 2019000091A MX 2019000091 A MX2019000091 A MX 2019000091A MX 2019000091 A MX2019000091 A MX 2019000091A MX 2019000091 A MX2019000091 A MX 2019000091A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- relates
- present
- bone metastasis
- metastasis
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 238000004393 prognosis Methods 0.000 title abstract 2
- 206010005949 Bone cancer Diseases 0.000 title 1
- 208000018084 Bone neoplasm Diseases 0.000 title 1
- 206010027476 Metastases Diseases 0.000 abstract 7
- 230000009401 metastasis Effects 0.000 abstract 7
- 210000000988 bone and bone Anatomy 0.000 abstract 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 101150095688 maf gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 abstract 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente invención se refiere a un método para el pronóstico de metástasis ósea en cáncer de mama HER2 +, que comprende determinar si el gen MAF se amplifica en una muestra de tumor primario. Asimismo, la presente invención también se refiere a un método para la determinación de la tendencia a desarrollar metástasis en los huesos con respecto a metástasis en otros órganos, que comprende la determinación del nivel de expresión, amplificación o translocación del gen MAF. La presente invención también se refiere a un método para predecir la metástasis ósea temprana en un sujeto que sufra de cáncer de mama. La presente invención también se refiere a un inhibidor de c-Maf como agente terapéutico para uso en el tratamiento de metástasis de cáncer de mama HER2+. La presente invención se refiere a kits para la predicción de la metástasis ósea y predecir el resultado clínico de un sujeto que padezca metástasis ósea. Finalmente, la presente invención se refiere a un método para la tipificación de un sujeto que sufra de cáncer de mama y para la clasificación de un sujeto con cáncer de mama en una cohorte.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888984P | 2013-10-09 | 2013-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000091A true MX2019000091A (es) | 2023-04-27 |
Family
ID=52292968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004557A MX362041B (es) | 2013-10-09 | 2014-10-07 | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| MX2019000091A MX2019000091A (es) | 2013-10-09 | 2016-04-08 | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004557A MX362041B (es) | 2013-10-09 | 2014-10-07 | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170101683A1 (es) |
| EP (2) | EP3524698A1 (es) |
| JP (1) | JP6550045B2 (es) |
| KR (1) | KR20160061424A (es) |
| CN (1) | CN105980576B (es) |
| AU (1) | AU2014333513B2 (es) |
| BR (1) | BR112016007864A2 (es) |
| CA (1) | CA2926894A1 (es) |
| DK (1) | DK3055429T3 (es) |
| ES (1) | ES2727904T3 (es) |
| MX (2) | MX362041B (es) |
| TR (1) | TR201907389T4 (es) |
| WO (1) | WO2015052583A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102240323B1 (ko) | 2010-10-06 | 2021-04-14 | 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) | 유방암 전이의 진단, 예후 및 치료 방법 |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| DK2859120T3 (en) | 2012-06-06 | 2019-01-14 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Method for diagnosis and prognosis of lung cancer metastasis |
| CN104995313A (zh) | 2012-10-12 | 2015-10-21 | 生物运动有限公司 | 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| KR102571924B1 (ko) | 2016-05-25 | 2023-08-28 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
| CN105907886A (zh) * | 2016-07-07 | 2016-08-31 | 蔡维泺 | miR-124在乳腺癌骨转移疾病中的应用 |
| KR20200104298A (ko) * | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
| WO2019232283A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| RU2766248C1 (ru) * | 2021-01-11 | 2022-02-10 | Федеральное государственное бюджетное научное учреждение "Томский национальной исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") | Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в первичной опухоли у больных раком молочной железы |
| RU2757960C1 (ru) * | 2021-01-11 | 2021-10-25 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в метастатических лимфатических узлах у больных раком молочной железы |
| CN113667748B (zh) * | 2021-07-19 | 2023-07-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用 |
| CN114512183B (zh) * | 2022-01-27 | 2022-09-20 | 北京吉因加医学检验实验室有限公司 | 一种预测met基因扩增或多倍体的方法及装置 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004920A1 (en) | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| JP4138013B2 (ja) | 1996-12-23 | 2008-08-20 | イミュネックス・コーポレーション | Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US6982475B1 (en) | 1998-03-20 | 2006-01-03 | Mcsp, Llc | Hermetic wafer scale integrated circuit structure |
| PL350456A1 (en) | 1999-03-15 | 2002-12-16 | Axys Pharmaceuticals | N−cyanomethylamides as protease inhibitors |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| AU779855B2 (en) | 2000-01-06 | 2005-02-17 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| TR201809008T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| CN1898563B (zh) * | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | 诊断乳腺癌的方法 |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| CA2632451C (en) | 2005-12-06 | 2015-11-03 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| US20110130296A1 (en) | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| SG176073A1 (en) * | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| ES2546410T3 (es) | 2009-08-06 | 2015-09-23 | John Wayne Cancer Institute | Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico |
| KR102240323B1 (ko) * | 2010-10-06 | 2021-04-14 | 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) | 유방암 전이의 진단, 예후 및 치료 방법 |
| EP2685988A4 (en) * | 2011-03-15 | 2014-08-20 | Univ North Carolina | METHOD FOR THE TREATMENT OF BREAST CANCER WITH ANTHRACYCLIN THERAPY |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
-
2014
- 2014-10-07 DK DK14824529.3T patent/DK3055429T3/en active
- 2014-10-07 CN CN201480064111.7A patent/CN105980576B/zh active Active
- 2014-10-07 WO PCT/IB2014/002675 patent/WO2015052583A2/en active Application Filing
- 2014-10-07 AU AU2014333513A patent/AU2014333513B2/en active Active
- 2014-10-07 MX MX2016004557A patent/MX362041B/es active IP Right Grant
- 2014-10-07 TR TR2019/07389T patent/TR201907389T4/tr unknown
- 2014-10-07 CA CA2926894A patent/CA2926894A1/en not_active Abandoned
- 2014-10-07 KR KR1020167011949A patent/KR20160061424A/ko not_active Application Discontinuation
- 2014-10-07 US US15/027,946 patent/US20170101683A1/en not_active Abandoned
- 2014-10-07 EP EP19165007.6A patent/EP3524698A1/en not_active Withdrawn
- 2014-10-07 JP JP2016521355A patent/JP6550045B2/ja active Active
- 2014-10-07 ES ES14824529T patent/ES2727904T3/es active Active
- 2014-10-07 BR BR112016007864A patent/BR112016007864A2/pt not_active Application Discontinuation
- 2014-10-07 EP EP14824529.3A patent/EP3055429B1/en active Active
-
2016
- 2016-04-08 MX MX2019000091A patent/MX2019000091A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX362041B (es) | 2019-01-07 |
| EP3524698A1 (en) | 2019-08-14 |
| AU2014333513A1 (en) | 2016-04-28 |
| EP3055429B1 (en) | 2019-03-27 |
| JP2016539625A (ja) | 2016-12-22 |
| JP6550045B2 (ja) | 2019-07-24 |
| US20170101683A1 (en) | 2017-04-13 |
| MX2016004557A (es) | 2016-07-22 |
| WO2015052583A2 (en) | 2015-04-16 |
| AU2014333513B2 (en) | 2020-11-26 |
| CA2926894A1 (en) | 2015-04-16 |
| WO2015052583A3 (en) | 2015-07-23 |
| CN105980576A (zh) | 2016-09-28 |
| EP3055429A2 (en) | 2016-08-17 |
| DK3055429T3 (en) | 2019-04-23 |
| KR20160061424A (ko) | 2016-05-31 |
| BR112016007864A2 (pt) | 2017-12-05 |
| TR201907389T4 (tr) | 2019-06-21 |
| CN105980576B (zh) | 2021-07-16 |
| ES2727904T3 (es) | 2019-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| MX2013003880A (es) | Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama. | |
| MX365421B (es) | Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| MX2014006404A (es) | Metodos y kits para el pronostico del cancer colorrectal. | |
| MX2018008169A (es) | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. | |
| WO2011094759A3 (en) | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies | |
| PH12014502410A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
| MX357429B (es) | Predictores para el tratamiento del cáncer. | |
| MY179845A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| MX2018009112A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. | |
| MX2013013153A (es) | La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon. | |
| Ng et al. | Non-invasive microrna signatures from the plasma of breast cancer patients reveals sensitive and specific marker for breast cancer screening | |
| UA82125U (ru) | Способ прогнозирования рефрактур у больных с ложными суставами | |
| UA108261U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA106708U (uk) | Спосіб прогнозування зрощення перелому | |
| UA99752U (uk) | Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози | |
| UA95656U (uk) | Спосіб прогнозування зрощення перелому | |
| PL410186A1 (pl) | Sposób, zastosowanie i zestaw do wykrywania wysokiego ryzyka raka piersi o złym rokowaniu |